(Q40440622)

20 September 2017

1 reference

title

Quinidine-induced rheumatic syndromes (English)

1 reference

20 September 2017

J. A. Alloway

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7604299

9 June 2024

M. P. Salata

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7604299

9 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7604299

9 June 2024

publication date

1 April 1995

1 reference

full work available at URL

20 September 2017

https://api.elsevier.com/content/article/PII:S0049017295800034?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0049-0172(95)80003-4

https://api.elsevier.com/content/article/PII:S0049017295800034?httpAccept=text/plain

9 June 2024

1 reference

https://api.crossref.org/works/10.1016/S0049-0172(95)80003-4

Seminars in Arthritis and Rheumatism

9 June 2024

published in

1 reference

20 September 2017

volume

24

1 reference

20 September 2017

issue

5

1 reference

20 September 2017

page(s)

315-322

1 reference

Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Quinidine-induced systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Quinidine-Induced Lupus Nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Quinidine-lnduced Lupus Erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Quinidine induced lupus syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Procainamide, quinidine, and lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Quinidine-induced lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Two distinct quinidine-induced rheumatic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Polyarthritis complicating quinidine treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Skeletal muscle weakness resulting from quinidine ingestion.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

High-renin hypertension in necrotizing vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Procainamide-induced serologic changes in asymptomatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

IgG antibodies to the histone complex H2A-H2B characterize procainamide-induced lupus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Hemolytic anemia due to quinidine: observations on its mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Immunomodulatory effect of procainamide in man. Inhibition of human suppressor T-cell activity in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Lymphocyte alteration by procainamide: relation to drug-induced lupus erythematosus syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Multiform quinidine toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Polymyositis and penicillamine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980003-4

7 January 2021

Quinidine-induced lupus erythematosus-like syndrome: three case reports and a review of the literature

series ordinal

12

1 reference

https://api.crossref.org/works/10.1016/S0049-0172(95)80003-4

9 June 2024

Identifiers

1 reference

20 September 2017

1 reference